695 Millennium - Seventeenth Edition SCIENCES, PHARMACEUTICALS AND BIOTECHNOLOGY for congenital diseases. A prolific writer in his area of expertise, Dr. Sper has authored and coauthored 14 peer-reviewed papers in scientific journals such as Frontiers, the Journal of Immunology, Science Translational Medicine, PLoS One, Theriogenology, the Open Journal of Obstetrics & Gynecology and the Equine Veterinary Journal. Originally hailing from Brazil, Dr. Sper completed his veterinary medicine education at the Federal University of Uberlândia before moving to the United States. He pursued a doctorate after four years of veterinary clinical training at North Carolina State University, where his passion for research blossomed, particularly in genetic technology and translational medicine for large animal models. After finishing his graduate work, he pivoted away from veterinary medicine and undertook a post-doctoral program at the University of California San Francisco Center for Maternal-Fetal Precision Medicine. Before accepting his current role at Mammoth Biosciences, he served as a scientist at GenEdit, a biotech company developing synthetic nanoparticles for genetic medicine delivery. As a testament to his research prowess, Dr. Sper holds two international and two national research awards from various university symposiums and conferences. To remain aware of developments in his field, he maintains his membership with the American Society of Gene & Cell Therapy. Dr. Sper attributes his success to persistence and patience. Moreover, he credits his success to fortuitously finding himself in the right place at the right time and surrounded by the right people. Looking toward the future, he aspires to become more highly regarded in his field and to continue helping those in need and advancing the knowledge and understanding of genetic medicine drug development and discovery. Driven by his passion to leave a lasting impact on the lives of others, Dr. Renan Bueno Sper has found success as a principal scientist at Mammoth Biosciences Inc. In this capacity, his research primarily focuses on gene editing technologies — particularly CRISPR — for the purpose of developing therapeutic treatments RENAN BUENO SPER, DVM, PHD PRINCIPAL SCIENTIST Mammoth Biosciences Inc. San Francisco, CA
RkJQdWJsaXNoZXIy MTQ5NDA2